EP0552292B1 - Substituted imidazobenzazepines and imidazopyridoazepines - Google Patents
Substituted imidazobenzazepines and imidazopyridoazepines Download PDFInfo
- Publication number
- EP0552292B1 EP0552292B1 EP91920026A EP91920026A EP0552292B1 EP 0552292 B1 EP0552292 B1 EP 0552292B1 EP 91920026 A EP91920026 A EP 91920026A EP 91920026 A EP91920026 A EP 91920026A EP 0552292 B1 EP0552292 B1 EP 0552292B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- alkyl
- representing
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 O*1ccccc1 Chemical compound O*1ccccc1 0.000 description 3
- MJVATKQPFBBTGG-UHFFFAOYSA-N O=CN(CC1)CCC1C(c1ncc[n]1C=Cc1c2)c1ccc2Cl Chemical compound O=CN(CC1)CCC1C(c1ncc[n]1C=Cc1c2)c1ccc2Cl MJVATKQPFBBTGG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the invention relates to compounds of the formula: wherein R1 is H, C1-C7 alkyl, C3-C7 cycloalkyl, CF3, aryl, substituted aryl, heteroaryl, -O-C1-C7 alkyl, or -O-C3-C7 cycloalkyl; R2 and R3 are each independently H, C1-C7 alkyl, C3-C7 cycloalkyl, CF3, NO2, halogen, OR7, NR8R9 or S(O) m R10, wherein m is 0, 1 or 2; R4 is H, C1-C7 alkyl, arylmethyl, or substituted arylmethyl; R5 and R6 are each independently H, C1-C7 alkyl, C3-C7 cycloalkyl, aryl, substituted aryl, heteroaryl, arylmethyl, substituted arylmethyl, or taken together constitute a chain of (CH2) k groups, wherein
- One group of preferred compounds of formula 1.0 are those wherein one and only one of the dotted lines a and b is a carbon-carbon bond and Q is CH. Another group of preferred compounds are those wherein Q represents N or NO.
- R1 is C1-C7 alkyl and R2 is H or chlorine meta to the Q position.
- R1 is and R2 is H or chlorine meta to the Q postion.
- Still another preferred compound of formula 1.0 is
- Exemplary compounds of the invention are: and
- a most preferred compound of the invention is:
- the compounds of formula 1.0 are useful in treating allergic reactions in mammals, e.g. man.
- the compounds of formula 1.0 may be used to treat any condition in which mediation of PAF is involved.
- these compounds are useful as agents for the treatment of asthma and other allergic diseases. These compounds are also useful as agents in the treatment of inflammation. In particular, these compounds are useful for the oral treatment of asthma and other allergic diseases and the oral treatment of inflammation.
- the invention also relates to pharmaceutical compositions for treating allergic diseases which comprise an anti-allergically effective amount of a compound of formula 1.0 and an inert pharmaceutical carrier material.
- pharmaceutical compositions for treating inflammation which comprise an anti-inflammatory effective amount of a compound of formula 1.0 and an inert pharmaceutical carrier material.
- the invention also relates to a method for treating allergic diseases which comprises administering to a host in need of such treatment an anti-allergically effective amount of a compound of formula 1.0.
- the invention also relates to a method for treating inflammation which comprises administering to a host in need of such treatment an anti-inflammatory effective amount of a compound of formula 1.0.
- Compounds of formula 1.0 of the invention form pharmaceutically acceptable acid addition salts with any of a variety of inorganic and organic acids.
- suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and the like.
- the free base forms may be regenerated by treating the salt form with a base.
- a base for example, dilute aqueous base solutions may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate solutions are suitable for this purpose.
- the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for the purposes of this invention.
- Certain compounds of the invention may exist in isomeric forms.
- the invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures.
- alkyl denotes a straight or branched chain saturated hydrocarbon of up to 10 carbon atoms. The number of carbon atoms may be designated.
- C1-C7 alkyl (including the alkyl portions of C1-C7 alkoxy, etc.) - represents a straight or branched, saturated hydrocarbon chain having from 1 to 7, carbon atoms.
- Cycloalkyl denotes a saturated hydrocarbon ring of 3 to 10 carbon atoms. The number of carbon atoms may be designated. For example, “C3-C7" cycloalkyl refers to rings of 3 to 7 carbon atoms.
- Aryl (including the aryl portion of arylmethyl, etc.) - denotes a carbocyclic group having from 6 to 14 carbon atoms and having at least one benzenoid ring with all available suitable carbon atoms of the carbocyclic group being intended as possible points of attachment.
- substituted aryl (including the substituted aryl portion of substituted arylmethyl) denotes an aryl wherein 1 to 3 hydrogen atoms thereof are replaced by the same or different substituents each independently selected from the group consisting of halogen, alkyl, hydroxy, alkoxy, phenoxy, amino, alkylamino, and dialkylamino.
- substituents are halogen or C1-C7 alkyl. In particular, chlorine, methyl and ethyl are preferred substituents.
- “Herteroaryl” denotes a cyclic group having at least one O, S and/or N interrupting a carbocyclic ring structure, and where the heteroatom is N, optionally including N-oxides thereof, and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic group having from 2 to 14, preferably from 2 to 10 carbon atoms.
- heteroaryl The following groups exemplify "heteroaryl", but the invention is not limited to these groups: 2-, 3- or 4-pyridyl or N-oxides thereof, 2- or 3-furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-imidazolyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6-[1,2,4-triazinyl], 3- or 5-[1,2,4-thiadizolyl], 2-, 3-, 4-, 5-, 6- or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, etc.
- Preferred heteroaryl groups are 2-, 3-or 4-pyridyl, or N-oxides thereof.
- substituted heteroaryl denotes a heteroaryl wherein 1 to 3 hydrogen atoms bonded to carbon atoms are replaced by the same or different substituents each independently selected from the group consisting of halogen, alkyl, hydroxy, alkoxy, phenoxy, amino, alkylamino, and dialkylamino.
- substituents are halogen or C1-C7 alkyl. In particular, chlorine, methyl and ethyl are preferred substituents.
- halogen which is used interchangeably with the term “halo”, denotes chlorine, fluorine, bromine, and iodine.
- chlorine meta to the Q position means a chlorine in the following position: Where a line is drawn into a ring, it represents a bond at any position available for bonding on the ring. Thus represents 2-, 3-, or 4-pyridyl N-oxides.
- the compounds of the invention may be administered in a conventional manner such as orally, rectally, or parenterally. Preferably, the compounds of the invention are administered orally.
- inert, pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be an encapsulating material.
- the carrier is a finely divided solid which is in admixture with the finely divided active compound.
- the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from 5 or 10 to about 70 percent of the active ingredient.
- Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like.
- preparation is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it.
- carrier provides a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it.
- cachets are included. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol.
- Aqueous solutions suitable for oral use can be prepared by adding the active component in water and adding suitable colorants, flavors, stabilizing, sweetening, solubilizing and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
- liquid forms include solutions, suspensions and emulsions.
- solid form preparations are most conveniently provided in unit dose form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as with a syringe, teaspoon or other volumetric container. When multiple liquid doses are so prepared, it is preferred to maintain the unused portion of said liquid doses at low temperature (i.e., under refrigeration) in order to retard possible decomposition.
- the solid form preparations intended to be converted to liquid form may contain, in addition to the active material, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersions, thickeners, solubilizing agents and the like.
- the solvent utilized for preparing the liquid form preparation may be water, isotonic water, ethanol, glycerine, propylene glycol and the like as well as mixtures thereof. Naturally, the solvent utilized will be chosen with regard to the route of administration, for example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.
- the pharmaceutical preparation is in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparations, for example, packeted tablets, capsules and powders in vials or ampoules.
- the unit dosage form can also be a capsule, cachet or tablet itself or it can be the appropriate number of any of these in packaged form.
- the quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to 100 mg according to the particular application and the potency of the active ingredient.
- a typical recommended dosage is from about 0.01 mg/kg to 1000 mg/kg, preferably about 1 mg/kg to about 100 mg/kg, preferably orally.
- the daily dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated and the particular compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- the compounds of formula 1.0 possess PAF antagonistic properties. These compounds are, therefore, useful when PAF is a factor in the disease or disorder. This includes allergic diseases such as asthma, adult respiratory distress syndrome, urticaria and inflammatory diseases such as rheumatoid arthritis and osteoarthritis.
- PAF is an important mediator of such processes as platelet aggregation, smooth muscle contraction (especially in lung tissue), vascular permeability and neutrophil activation.
- Recent evidence implicates PAF as an underlying factor involved in airway hyperreactivity, shock, edema, hypersensitivity, disseminated loss of platelets by pregnant women, and in diseases associated with implantation of embryo in utero .
- the compounds of formula 1.0 of the invention can be used to treat allergy and inflammatory caused diseases and their preferred use is for treating allergic chronic obstructive lung diseases.
- Chronic obstructive lung disease as used herein means disease conditions in which the passage of air through the lungs is obstructed or diminished such as is the case in asthma, bronchitis and the like.
- Platelet-activating factor causes aggregation of platelets by a receptor-mediated mechanism. Therefore, PAF-induced platelet aggregation provides a simple and convenient assay to screen compounds for PAF antagonism.
- Human blood (50 ml) was collected from healthy male donors in an anticoagulant solution (5 ml) containing sodium citrate (3.8%) and dextrose (2%). Blood was centrifuged at 110 X g for 15 min. and the supernatant platelet-rich plasma (PRP) carefully transferred into a polypropylene tube. Platelet-poor-plasma (PPP) was prepared by centrifuging PRP at 12,000 X g for 2 min. in a Beckman Microfuge B. PRP was used within 3 hours of drawing the blood.
- PRP platelet-poor-plasma
- BSA bovine serum albumin
- Collagen (Sigma) and adenosine diphosphate (ADP)(Sigma) were purchased as solutions. Test compounds were initially dissolved in dimethyl sulfoxide (DMSO) at a concentration of 50 mM and then further diluted in Hepes-saline-BSA buffer to achieve appropriate concentrations. Hepes is an abbreviation for (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]).
- a standard PAF antagonist such as 8-chloro-6,11-(1-acetyl-4-piperidylidene-5H-benzo[5,6]cyclohepta[1,2-b]pyridine was used as a positive control.
- the inhibitory concentration is the concentration of compound in micromoles per liter at which 50% of the aggregation is inhibited, as measured by the light transmission through each sample of PRP as compared to that through PPP.
- IC50 (»M) 5 for 4-(5,6-dihydro-11H-imidazo[2,1- b ][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N1-oxide.
- IC50(»M) 35 for 1-acetyl-4-(5,6-dihydro-11H-imidazo[2,1- b ][3]benzazepin-11-ylidene)-piperidine.
- the compounds of formula 1.0 of the invention may also be demonstrated to be active by the following in vivo PAF Antagonist Test.
- Non-sensitized guinea pigs are fasted overnight, and the following morning anesthetized with 0.9 ml/kg i.p. of dialurethane (0.1 g/ml of diallybarbituric acid, 0.4 g/ml of ethylurea and 0.4 g/ml of urethane).
- the trachea is cannulated and the animals are ventilated by a Harvard rodent respirator at 55 strokes/min. with a stroke volume of 4 ml.
- a side arm to the tracheal cannula is connected to a Harvard pressure transducer to obtain a continuous measure of intratracheal pressure, which is recorded on a Harvard polygraph.
- the jugular vein is cannulated for the administration of compounds.
- the animals are challenged i.v. with PAF (0.4 »g/kg in isotonic saline containing 0.25% bovine serum albumin(BSA)) and the peak increase in inflation pressure that occurred within 5 min. after challenge is recorded.
- Test compounds can be administered either orally (2 hrs. prior to PAF as a suspension in 0.4% methylcellulose vehicle) or intravenously (10 min. prior to PAF as a solution in dimethylsulfoxide).
- the Aldrich Chemical Company supplied (2-bromoethyl)benzene and 1-acetylimidazole.
- the term "active compound” is used to designate the compound 4-(5,6-dihydro-11H-imidazo[2,1- b ][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N1-oxide.
- active compound is used to designate the compound 4-(5,6-dihydro-11H-imidazo[2,1- b ][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N1-oxide.
- the scope of the invention in its pharmaceutical composition aspect is not to be limited by the example provided since any other compound of formula 1.0 can be substituted into the pharmaceutical composition example.
- the active compound may be any compound of the invention, such as 4-(5,6-dihydro-11H-imidazo[2,1- b ][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N1-oxide
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The invention relates to compounds of the formula:
wherein R¹ is H, C₁-C₇ alkyl, C₃-C₇ cycloalkyl, CF₃, aryl, substituted aryl, heteroaryl, -O-C₁-C₇ alkyl, or -O-C₃-C₇ cycloalkyl; R² and R³ are each independently H, C₁-C₇ alkyl, C₃-C₇ cycloalkyl, CF₃, NO₂, halogen, OR⁷, NR⁸R⁹ or S(O)mR¹⁰, wherein m is 0, 1 or 2; R⁴ is H, C₁-C₇ alkyl, arylmethyl, or substituted arylmethyl; R⁵ and R⁶ are each independently H, C₁-C₇ alkyl, C₃-C₇ cycloalkyl, aryl, substituted aryl, heteroaryl, arylmethyl, substituted arylmethyl, or taken together constitute a chain of (CH₂)k groups, wherein k is 3, 4, or 5; R⁷, R⁸ and R⁹ are each independently H, C₁-C₇ alkyl, -C(=O)-(C₁-C₇ alkyl), -C(=O)aryl, or -C(=O)heteroaryl; R¹⁰ is C₁-C₇ alkyl, C₃-C₇ cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylmethyl, or substituted arylmethyl; one and only one of the dotted lines, a, b, c, and d, represents a carbon-carbon bond; n is 0,1, 2, or 3; Z is O or S, Q is CH, N or NO, with the proviso that Z is not S when Q is NO, or pharmaceutically acceptable acid addition salts thereof. - One group of preferred compounds of formula 1.0 are those wherein one and only one of the dotted lines a and b is a carbon-carbon bond and Q is CH. Another group of preferred compounds are those wherein Q represents N or NO.
- More preferred are compounds of formula 1.0 wherein the dotted line b represents a carbon-carbon bond; Q is CH; R¹ is H, C₁-C₇ alkyl or heteroaryl; R² is H or halogen; R³ is H or halogen; R⁴ is H; R⁵ and R⁶ are each H; and n is 1.
-
- Also preferred are compounds as described just above wherein R¹ is C₁-C₇ alkyl and R² is H or chlorine meta to the Q position.
-
-
-
-
- Due to their platelet activating factor(PAF)-antagonist activity, the compounds of formula 1.0 are useful in treating allergic reactions in mammals, e.g. man. In general, the compounds of formula 1.0 may be used to treat any condition in which mediation of PAF is involved.
- Specifically, these compounds are useful as agents for the treatment of asthma and other allergic diseases. These compounds are also useful as agents in the treatment of inflammation. In particular, these compounds are useful for the oral treatment of asthma and other allergic diseases and the oral treatment of inflammation.
- The invention also relates to pharmaceutical compositions for treating allergic diseases which comprise an anti-allergically effective amount of a compound of formula 1.0 and an inert pharmaceutical carrier material. The invention also relates to pharmaceutical compositions for treating inflammation which comprise an anti-inflammatory effective amount of a compound of formula 1.0 and an inert pharmaceutical carrier material.
- The invention also relates to a method for treating allergic diseases which comprises administering to a host in need of such treatment an anti-allergically effective amount of a compound of formula 1.0. The invention also relates to a method for treating inflammation which comprises administering to a host in need of such treatment an anti-inflammatory effective amount of a compound of formula 1.0.
- Compounds of formula 1.0 of the invention form pharmaceutically acceptable acid addition salts with any of a variety of inorganic and organic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and the like.
- The free base forms may be regenerated by treating the salt form with a base. For example, dilute aqueous base solutions may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate solutions are suitable for this purpose. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for the purposes of this invention.
- Certain compounds of the invention may exist in isomeric forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures.
- As used herein the term "alkyl" denotes a straight or branched chain saturated hydrocarbon of up to 10 carbon atoms. The number of carbon atoms may be designated. For example, "C₁-C₇ alkyl" (including the alkyl portions of C₁-C₇ alkoxy, etc.) - represents a straight or branched, saturated hydrocarbon chain having from 1 to 7, carbon atoms.
- "Cycloalkyl" denotes a saturated hydrocarbon ring of 3 to 10 carbon atoms. The number of carbon atoms may be designated. For example, "C₃-C₇" cycloalkyl refers to rings of 3 to 7 carbon atoms.
- "Aryl" (including the aryl portion of arylmethyl, etc.) - denotes a carbocyclic group having from 6 to 14 carbon atoms and having at least one benzenoid ring with all available suitable carbon atoms of the carbocyclic group being intended as possible points of attachment.
- The term "substituted aryl" (including the substituted aryl portion of substituted arylmethyl) denotes an aryl wherein 1 to 3 hydrogen atoms thereof are replaced by the same or different substituents each independently selected from the group consisting of halogen, alkyl, hydroxy, alkoxy, phenoxy, amino, alkylamino, and dialkylamino. Preferred substituents are halogen or C₁-C₇ alkyl. In particular, chlorine, methyl and ethyl are preferred substituents.
- "Herteroaryl" denotes a cyclic group having at least one O, S and/or N interrupting a carbocyclic ring structure, and where the heteroatom is N, optionally including N-oxides thereof, and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic group having from 2 to 14, preferably from 2 to 10 carbon atoms. The following groups exemplify "heteroaryl", but the invention is not limited to these groups: 2-, 3- or 4-pyridyl or N-oxides thereof, 2- or 3-furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-imidazolyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6-[1,2,4-triazinyl], 3- or 5-[1,2,4-thiadizolyl], 2-, 3-, 4-, 5-, 6- or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, etc. Preferred heteroaryl groups are 2-, 3-or 4-pyridyl, or N-oxides thereof.
- The term "substituted heteroaryl" denotes a heteroaryl wherein 1 to 3 hydrogen atoms bonded to carbon atoms are replaced by the same or different substituents each independently selected from the group consisting of halogen, alkyl, hydroxy, alkoxy, phenoxy, amino, alkylamino, and dialkylamino. Preferred substituents are halogen or C₁-C₇ alkyl. In particular, chlorine, methyl and ethyl are preferred substituents.
- The term "halogen", which is used interchangeably with the term "halo", denotes chlorine, fluorine, bromine, and iodine.
-
- Compounds of formula 1.0 and intermediates thereof are prepared by processes (a) through (j) below in which R¹, R², R³, R⁴, R⁵, R⁶, Q, Z, a, b, c, d and n are as above unless otherwise noted.
- (a) A compound (1.1) of formula 1.0, wherein Q is CH or N-O and wherein T is C(=Z)R¹, or of formula 3.0, wherein T is H, is made by reacting a compound of formula 2.0, wherein Q is CH or N-O and in which T is C(=Z)R¹, or of formula 2.0, wherein T is H, with an acid:
The reaction can be carried out at temperatures from about -10 °C to + 150 °C, and is preferably carried out at about +25 °C to +100 °C. - (b) A compound (1.2) of formula 1.0, wherein Q is CH or N-O, is made by allowing a compound of formula 3.0, wherein Q is CH, N, or N-O, to react with an organic carboxylic acid, R¹CO₂H, and a coupling reagent, which is described below:
Other methods for making compounds 1.2 from compounds 3.0 are well known to those skilled in the art; e.g., a reaction between compound 3.0 and the acid chloride, R¹COCl, corresponding to the acid R¹CO₂H also leads to compounds 1.2. - (c) A compound (1.4) of formula 1.0, wherein Q is CH or N, is made by allowing a compound of formula 1.3, wherein Q is CH, N, or N-O, to react with a deoxygenating reagent:
Suitable deoxygenating reagents are hexamethyldisilane combined with tetrabutylammonium fluoride, butadiene sulfone, diphosphorous tetraiodide, sodium hypophosphite combined with palladium on carbon, and phosphorous trichloride. A preferred reagent is the last of these. The reaction is carried out at temperatures from about - 15° C to about + 100 ° C, and a preferred temperature is about + 25° C. The reaction is preferably carried out in a solvent and suitable solvents are chlorocarbons, e.g., chloroform, carbon tetrachloride, dichloromethane, and ethylenedichloride, and the like. Dichloromethane is a preferred solvent. - (d) A compound (1.3) of formula 1.0, wherein Q is CH, N, or N-O, is made by allowing a compound of formula 1.4, wherein Q is CH, N, or N-O, and R1' is as described above, to react with a peroxidizing reagent:
When Q is N, the above reaction is carried using a molar excess (preferably about 2:1) of a compound of formula 1.4 as compared to the peroxidizing agent. The reaction product under such conditions is a mixture of four compounds. One compound is the unchanged compound of formula 1.4. In another compound, Q has been converted to NO and
In the desired compound of formula 1.3, Q remains unchanged as N while
This desired product of formula 1.3 can be isolated by conventional separatory techniques.
In general, a reaction similar to the above reaction may be used to convert compounds of formula 1.0 wherein Q is CH, N or NO and R¹ is a nitrogen containing heteroaryl moiety excluding N-oxides, to the corresponding heteroaryl N-oxides thereof. - (e) A compound (1.6) of formula 1.0 is made by allowing a compound (1.2) wherein Q is CH, N, or NO to react with a sulfurating agent, e.g., Lawesson's reagent or P₂S₅:
Intermediate compounds 2.0-10.0 of this invention are known or could be prepared by known methods or are prepared by processes (f) through (i) below: - (f) An intermediate compound of formula 2.0, is prepared by allowing an intermediate compound of formula 5.0 to acylate an intermediate compound of formula 4.0.
In some cases, the reaction of compounds 4.0 and 5.0 may also produce a compound of formula 6.0 below that is admixed with a compound of formula 2.0. - (g) An intermediate compound of formula 2.0 is also made by allowing an alkali metal hydroxide, such as sodium hydroxide or potassium hydroxide; or an alkali metal carbonate, such as sodium or potassium carbonate, or an aqueous acid, to hydrolyze an intermediate compound of formula 6.0:
- (h) A compound of formula 4.0 is made by allowing a compound of formula 7.0, wherein L is a leaving group, such as a halide like chloride, bromide, or iodide or an alkyl or aryl sulfonate, like such as -OSO₂-(C₁-C₇ alkyl), -SO₂-(C₃-C₇ cycloalkyl) or -OSO₂-aryl, to react with a compound of formula 8.0, in which R¹¹ is chosen from H, C(=O)-(C₁-C₇ alkyl), (C=O)-(C₃-C₇ cycloalkyl), C(=O)-aryl, C(=O)heteroaryl, or an alkali metal :
Compounds of formula 7.0 are well known to one skilled in the art, and are commercially available, e.g., phenethyl bromide from the Aldrich Chemical Company, or are readily prepared by standard methods from commercially available compounds, e.g., 3-chlorophenethyl alcohol, also from the Aldrich Chemical Company. Compounds of formula 8.0 are known and are available commercially or can be prepared by known methods.
The reaction of an intermediate compound of formula 7.0 with an intermediate compound of formula 8.0 may also form an intermediate compound of formula 9.0 below. - (i) A compound of formula 4.0 also may be prepared by allowing a compound of formula 9.0 to react with an alkali or alkaline metal hydroxide or alkoxide, e.g., ⁻O-(C₁-C₇) alkyl, -O-(C₃-C₇ cycloalkyl):
- (j) A compound of formula 5.0 is made by allowing a compound of formula 10.0 to react with a reagent such as thionyl chloride, phosphorous oxychloride, phosphorous pentachloride oxalyl chloride, phosgene, and the like:
- The compounds of the invention may be administered in a conventional manner such as orally, rectally, or parenterally. Preferably, the compounds of the invention are administered orally.
- For preparing pharmaceutical compositions from the compounds of formula 1.0 of the invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be an encapsulating material.
- In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compound. In the tablet the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
- For preparing suppositories, a low melting wax such as mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol. Aqueous solutions suitable for oral use can be prepared by adding the active component in water and adding suitable colorants, flavors, stabilizing, sweetening, solubilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents.
- Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. These particular solid form preparations are most conveniently provided in unit dose form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as with a syringe, teaspoon or other volumetric container. When multiple liquid doses are so prepared, it is preferred to maintain the unused portion of said liquid doses at low temperature (i.e., under refrigeration) in order to retard possible decomposition. The solid form preparations intended to be converted to liquid form may contain, in addition to the active material, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersions, thickeners, solubilizing agents and the like. The solvent utilized for preparing the liquid form preparation may be water, isotonic water, ethanol, glycerine, propylene glycol and the like as well as mixtures thereof. Naturally, the solvent utilized will be chosen with regard to the route of administration, for example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.
- Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparations, for example, packeted tablets, capsules and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet or tablet itself or it can be the appropriate number of any of these in packaged form.
- The quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to 100 mg according to the particular application and the potency of the active ingredient. A typical recommended dosage is from about 0.01 mg/kg to 1000 mg/kg, preferably about 1 mg/kg to about 100 mg/kg, preferably orally.
- The daily dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated and the particular compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- The compounds of formula 1.0 possess PAF antagonistic properties. These compounds are, therefore, useful when PAF is a factor in the disease or disorder. This includes allergic diseases such as asthma, adult respiratory distress syndrome, urticaria and inflammatory diseases such as rheumatoid arthritis and osteoarthritis. For example, PAF is an important mediator of such processes as platelet aggregation, smooth muscle contraction (especially in lung tissue), vascular permeability and neutrophil activation. Recent evidence implicates PAF as an underlying factor involved in airway hyperreactivity, shock, edema, hypersensitivity, disseminated loss of platelets by pregnant women, and in diseases associated with implantation of embryo in utero.
- In particular, the compounds of formula 1.0 of the invention can be used to treat allergy and inflammatory caused diseases and their preferred use is for treating allergic chronic obstructive lung diseases. Chronic obstructive lung disease as used herein means disease conditions in which the passage of air through the lungs is obstructed or diminished such as is the case in asthma, bronchitis and the like.
- Activity of compounds of formula 1.0 of the invention was demonstrated by the procedures set forth below.
- Platelet-activating factor (PAF) causes aggregation of platelets by a receptor-mediated mechanism. Therefore, PAF-induced platelet aggregation provides a simple and convenient assay to screen compounds for PAF antagonism.
- Human blood (50 ml) was collected from healthy male donors in an anticoagulant solution (5 ml) containing sodium citrate (3.8%) and dextrose (2%). Blood was centrifuged at 110 X g for 15 min. and the supernatant platelet-rich plasma (PRP) carefully transferred into a polypropylene tube. Platelet-poor-plasma (PPP) was prepared by centrifuging PRP at 12,000 X g for 2 min. in a Beckman Microfuge B. PRP was used within 3 hours of drawing the blood.
- PAF was dissolved in chloroform:methanol (1:1, v/v) at a concentration of 2 mg/ml and stored at -70 C. An aliquot of this solution was transferred to a polypropylene tube and dried under a flow of nitrogen gas. To the dried sample was added Hepes-saline-BSA (BSA =bovine serum albumin) buffer (25 mM Hepes, pH 7.4, 1254 mM NaCl, 0.7 mM MgCl₂ and 0.1% BSA buffer) to obtain a 1 mM solution. The solution was sonicated for 5 min. in a bath sonicator. This stock solution was further diluted to appropriate concentrations in Hepes-saline-BSA butter. Collagen (Sigma) and adenosine diphosphate (ADP)(Sigma) were purchased as solutions. Test compounds were initially dissolved in dimethyl sulfoxide (DMSO) at a concentration of 50 mM and then further diluted in Hepes-saline-BSA buffer to achieve appropriate concentrations. Hepes is an abbreviation for (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]).
- When an aggregating agent such as PAF is added to PRP, platelets aggregate. An aggregometer quantifies this aggregation by measuring and comparing light (infra-red) transmission through PPP and PRP. Aggregation assays were performed using a dual-channel aggregometer (Model 440, Chrono-Log Corp., Havertown, PA). PRP(0.45 ml) in aggregometer cuvettes was continually stirred (37 C). Solutions (50 microliters ) of test compounds or vehicle were added to the PRP and, after incubation for 2 minutes, 10-15»l aliquots of PAF solution were added so as to achieve a final PAF concentration of 10-15 x 10⁻⁸M. Incubations were continued until the increase in light transmission reached a maximum (usually 2 min. ). This increase in light transmission reflecting plate/et aggregation is transmitted to a computer by the Chrono-Log model 810 AGGRO/LINK interface(Supplied by the Chrono-Log Corp. Havertown, PA). The AGGRO/LINK calculates the slope of the transmission change, thus providing the rate of aggregation. Values for inhibition were calculated by comparing rates of aggregation obtained in the absence and the presence of the compound. For each experiment, a standard PAF antagonist such as 8-chloro-6,11-(1-acetyl-4-piperidylidene-5H-benzo[5,6]cyclohepta[1,2-b]pyridine was used as a positive control.
- Compounds that inhibit PAF-induced aggregation were tested against several other aggregating agents including collagen (0.2 mg/ml) and adenosine diphosphate(2 microMolar). Compounds showing no activity against these latter agents were considered to be specific PAF antagonists. Results are shown below.
- The inhibitory concentration (IC₅₀) is the concentration of compound in micromoles per liter at which 50% of the aggregation is inhibited, as measured by the light transmission through each sample of PRP as compared to that through PPP.
- By the above test the following IC₅₀ values were obtained:
IC₅₀ (»M) = 5 for 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N¹-oxide. - IC₅₀(»M) = 35 for 1-acetyl-4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-piperidine.
- At a 50»M dose, 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine inhibited in vitro platelet aggregation by 17%.
- The compounds of formula 1.0 of the invention may also be demonstrated to be active by the following in vivo PAF Antagonist Test.
-
- Non-sensitized guinea pigs are fasted overnight, and the following morning anesthetized with 0.9 ml/kg i.p. of dialurethane (0.1 g/ml of diallybarbituric acid, 0.4 g/ml of ethylurea and 0.4 g/ml of urethane). The trachea is cannulated and the animals are ventilated by a Harvard rodent respirator at 55 strokes/min. with a stroke volume of 4 ml. A side arm to the tracheal cannula is connected to a Harvard pressure transducer to obtain a continuous measure of intratracheal pressure, which is recorded on a Harvard polygraph. The jugular vein is cannulated for the administration of compounds. The animals are challenged i.v. with PAF (0.4 »g/kg in isotonic saline containing 0.25% bovine serum albumin(BSA)) and the peak increase in inflation pressure that occurred within 5 min. after challenge is recorded. Test compounds can be administered either orally (2 hrs. prior to PAF as a suspension in 0.4% methylcellulose vehicle) or intravenously (10 min. prior to PAF as a solution in dimethylsulfoxide).
- The following examples are illustrative of the invention and are not intended to limit it. Temperatures are in degrees Celsius unless otherwise indicated.
- A solution of phosphorous trichloride (0.25 ml) in dichloromethane (3 ml) was added to a solution of 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N¹-oxide (B, 0.4 g) and dichloromethane (5 ml). The reaction mixture was allowed to to stir overnight at 25° C in an atmosphere of nitrogen, and was then poured onto a mixture of ice and water. The resulting mixture was basified with concentrated aqueous ammonia, and the aqueous layer was extracted with dichloromethane. The dried (magnesium sulfate), filtered extracts were concentrated to give 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)piperidine (A, 0.34 g), m.p. 207-209° C from carbon tetrachloride.
4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1 - (4-pyridinylcarbonyl)-piperidine N¹-oxide (B) was prepared as described in Example 2. - 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.61 g) was added to a solution of 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine (C, 0.52 g), pyridine-4-carboxylic acid N-oxide (0.44 g) and 1-hydroxybenzotriazole hydrate (0.43 g) in dichloromethane (20 ml) at 0-5° C. The reaction mixture was then allowed to stir and to warm to 25° C overnight. Water and 1 M sodium bicarbonate solution were added, and the aqueous layer was extracted with dichloromethane. Combined organic extracts were washed sequentially with water and brine, and were dried, filtered, and concentrated to give 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N¹-oxide (B, 0.54 g), m.p. 155-159° C from carbon tetrachloride-dichloromethane.
6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1 - b][3]benzazepine (C) was prepared as described in Example 4. The Aldrich Chemical Company supplies 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, pyridine-4-carboxylic acid N-oxide, and 1-hydroxybenzotriazole hydrate. - A solution of 1-acetyl-4-[[1-(2-phenylethyl)-1H-imidazol-2-yl]carbonyl]piperidine (D, 1.12 g) in trifluoromethanesulfonic acid (12 ml) was heated 18 hrs. at 60° C under nitrogen. The solution was then cooled and poured over ice. The resulting mixture was neutralized with solid sodium bicarbonate, and the aqueous layer was extracted with dichloromethane. Combined extracts were sequentially washed with water and saturated aqueous sodium chloride solution. The dried and filtered organic solution was then concentrated to give an oil which crystallized from ether to afford 1-acetyl-4-(5,6-dihydro-11H-imidazo[1,2-b][3]benzazepine-11-ylidene)-piperidine (E, 0.83 g); FAB-MS: m/z 308 (100%, [C₁₉H₂₁N₃O + H]⁺).
1-acetyl-4-[[1-(2-phenylethyl)-1H-imidazol-2-yl]carbonyl]piperidine (D) was prepared as follows. - To a stirred, cooled (0-5° C) solution of 1 -(2-phenylethyl)-1H-imidazole (F, 3.00 g) and triethylamine (19.5 ml) in acetonitrile (75 ml) was added 4-(chlorocarbonyl)-1-(1-chloroethylidene)piperidinium chloride (G, 7.29 g). The resulting mixture was allowed to warm to 10° C and was stirred 3 hrs. It was diluted with water and was saturated with sodium bicarbonate. The mixture was extracted with dichloromethane. Combined extracts were washed sequentially with water and saturated aqueous sodium chloride solution. The dried and filtered extracts were concentrated to give an oil (6.40 g) which crystallized to afford 1-acetyl-4-[[1-(2-phenylethyl)-1H-imidazol-2-yl]carbonyl]piperidine (D, 1.45g ), m.p. 113-116° C from ethyl acetate.
- The mother liquor remaining after crystallization of 1-acetyl-4-[[1-(2-phenylethyl)-1H-imidazol-2-yl]carbonyl]piperidine (D) was chromatographed over silica gel. Dichloromethane-methanol-concentrated aqueous ammonia (97.5-2.25-0.25) eluted (1-acetyl-4-piperidinylidene)[1-(2-phenylethyl)-1H-imidazol-2-yl]methyl 1-acetyl-4-piperidine carboxylate (H) as an oil; MS: m/z 478 (10%, M⁺).
1-(2-phenylethyl)-1H-imidazole (F) and 4-(chlorocarbonyl)-1-(1-chloroethylidene)piperidinium chloride (G) were prepared as follows. - A stirred mixture of 1,3-bis(2-phenylethyl)-1H-imidazolium iodide (J, 16.5 g), potassium tert.-butoxide (9.16 g), and ethanol (165 ml) was refluxed 68 hrs. under nitrogen. The mixture was cooled to 25° C diluted with water, and concentrated to remove ethanol. The residue was partitioned between dichloromethane and water. Combined organic extracts were dried, filtered, and concentrated to give 1-(2-phenyl)-1H-ethyl]imidazole (F, 6.24 g), distilling at 200 ° C (oven temperature) at 0.25 mm of mercury.
- Chem. Pharm. Bull. Japan (31, 1213-1221 (1983)) teaches another method for making 1-(2-phenylethyl)-1H-imidazole F.
- Thionyl chloride (60 ml) was added slowly to a stirred solution of 1-acetyl-4-piperidinecarboxylic acid (l, 25.0 g) in dichloromethane (250 ml) at 25° C. The mixture was allowed to stir 2 hrs.and was then diluted with petroleum ether (35-65° C, 250 ml) to precipitate 4-(chlorocarbonyl)-1-(1-chloroethylidene)piperidinium chloride (G, 34 g) as a colorless solid, which was used directly in the next step.
- 1,3-bis(2-phenylethyl)-1H-imidazolium iodide (J) was prepared as follows.
- A solution of (2-bromoethyl)benzene (27.3 ml), sodium iodide (60.0 g), 1-acetylimidazole (22.2 g), and acetonitrile (220 ml) was refluxed 6.5 hrs. under nitrogen. The solution was cooled to 25° C and the acetonitrile was evaporated. Water and potassium carbonate were added to the oily residue, which was extracted with dichloromethane. Combined extracts were washed with water, dried, filtered, and concentrated to give 1,3-bis(2-phenylethyl)-1H-imidazolium iodide (J, 35.4 g), m.p. 145.5-147° C from ethyl acetate.
- The Aldrich Chemical Company supplied (2-bromoethyl)benzene and 1-acetylimidazole.
- A solution of 1-acetyl-4-(5,6-dihydro-11H-imidazo[1,2-b][3]benzazepine-11-ylidene)-piperidine (E, 3.7 g) concentrated hydrochloric acid (100 ml), and water (100 ml) was refluxed for 20 hrs. The solution was cooled and concentrated, and the residue was dissolved in water. The resulting solution was washed with ethyl acetate, and was then basified with 50% sodium hydroxide solution. The basic aqueous solution was extracted with dichloromethane, and combined extracts were washed with water. The dichloromethane solution was dried, filtered, and concentrated to give 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine (C, 2.95 g), m.p. 287-289° C from dichloromethane-methanol.
6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine (C) was also prepared as follows. - A mixture (3.87 g) of 1-acetyl-4-[[1-(2-phenylethyl)-1H-imidazol-2-yl]carbonyl]piperidine (D), (1-acetyl-4-piperidinylidene)[1-(2-phenylethyl)-1H-imidazol-2-yl]methyl 1-acetyl-4-piperidine carboxylate (H), and 6 N hydrochloric acid (100 ml) was refluxed for 20 hrs. The cooled reaction mixture was concentrated, and the residue was diluted with water. The resulting mixture was sequentially washed with ether and ethyl acetate. The acidic aqueous layer was basified with sodium hydroxide solution and was extracted with dichloromethane. The combined extracts were washed with water, dried, filtered, and concentrated to give [1-(2-phenyethyl)-1H-imidazol-2-yl](4-piperidinyl) methanone (K, 0.91 g), m.p. 230-232° C from dichloromethane-hexanes.
- A solution of [1-(2-phenyethyl)-1H-imidazol-2-yl](4-piperidinyl)methanone (K, 0.54 g) and trifluoromethanesulfonic acid (6.25 ml) was heated 18 hrs. at 60° C. The solution was then poured over a mixture of ice and water. The resulting mixture was extracted with dichloromethane, and combined extracts were washed with 1 M sodium bicarbonate solution. The dichloromethane solution was dried, filtered, concentrated, and chromatographed over silica gel. Dichloromethanemethanol-concentrated aqueous ammonia (95:4.5:0.5) eluted 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine (C, 0.34 g), MS: m/z 265 (75, M⁺).
- The following is an example of a pharmaceutical dosage form which contains a compound of the invention. As used herein, the term "active compound" is used to designate the compound 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N¹-oxide. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the example provided since any other compound of formula 1.0 can be substituted into the pharmaceutical composition example.
-
No. Ingredients mg/tablet mg/tablet 1. Active compound 100 500 2. Lactose USP 122 113 3. Corn Starch, Food Grade,as a 10% paste in Purified Water 30 40 4. Corn Starch, Food Grade 45 40 5. Magnesium Stearate 3 7 Total 300 700 - Mix Item Nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine.
- In the above example, the active compound may be any compound of the invention, such as 4-(5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-(4-pyridinylcarbonyl)-piperidine N¹-oxide
- While the present invention has been described in conjunction with the specific embodiments set forth above, many modifications, alternatives, and variations thereof will be apparent to those of ordinary skill in the art. All such modifications, alternatives, and variations are intended to fall within the spirit and scope of the present invention.
Claims (16)
- A process for preparing a compound of the formula(a) reacting a compound of formula 2.0, wherein Q is CH or N-O and in which T is C(=Z)R¹ with a suitable acid to produce a compound of formula 1.1; or reacting a compound of formula 2.0, wherein T is H, with a suitable acid to produce a compound of formula 3.0.(b) reacting a compound of formula 3.0, wherein Q is CH, N, or N-O, with an organic carboxylic acid, R¹CO₂H, and a suitable coupling reagent to produce a compound of formula 1.2:(c) reacting a compound of formula 1.3, wherein Q is N-O, with a suitable deoxygenating reagent to produce a compound of formula 1.4 wherein Q is N:(d) reacting a compound of formula 1.4, wherein Q is CH, N, or N-O, and R1' is as described above, with a suitable peroxiding reagent to produce a compound of formula 1.3:
- A process according to claim 1 wherein the produced compound is characterised by one and only one of the dotted lines a and b representing a carbon-carbon bond and Q representing CH.
- A process according to claim 2 wherein the produced compound is further characterized by the dotted line b representing a carbon-carbon bond; R¹ representing H, C₁-C₇ alkyl or heteroaryl; R² representing H or halogen; R³ representing H or halogen; R⁴ representing H; R⁵ and R⁶ each representing H; and n representing 1.
- A process according to any preceding claim wherein the produced compound is further characterized by Z representing O, and R³ representing H.
- A process according to claim 4 wherein the produced compound is further characterized by R¹ representing C₁-C₇ alkyl, and R² representing H or chlorine meta to the Q position.
- A process according to claim 1 wherein the produced compound is further characterized by Q representing N or NO.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59533190A | 1990-10-10 | 1990-10-10 | |
US595331 | 1990-10-10 | ||
PCT/US1991/007156 WO1992006981A1 (en) | 1990-10-10 | 1991-10-04 | Substituted imidazobenzazepines and imidazopyridoazepines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0552292A1 EP0552292A1 (en) | 1993-07-28 |
EP0552292B1 true EP0552292B1 (en) | 1995-06-21 |
Family
ID=24382815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91920026A Expired - Lifetime EP0552292B1 (en) | 1990-10-10 | 1991-10-04 | Substituted imidazobenzazepines and imidazopyridoazepines |
Country Status (9)
Country | Link |
---|---|
US (1) | US5393753A (en) |
EP (1) | EP0552292B1 (en) |
JP (1) | JPH089616B2 (en) |
AT (1) | ATE124045T1 (en) |
AU (1) | AU8902591A (en) |
CA (1) | CA2093797C (en) |
DE (1) | DE69110685T2 (en) |
HK (1) | HK186696A (en) |
WO (1) | WO1992006981A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101850A (en) * | 1991-06-13 | 1996-01-31 | Janssen Pharmaceutica Nv | 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them |
GR1001393B (en) * | 1992-10-12 | 1993-10-29 | Janssen Pharmaceutica Nv | ImidazoÄ2,1-bÜÄ3Übenzazepine derivatives, compositions and method of use. |
GR1001385B (en) * | 1992-10-12 | 1993-10-29 | Janssen Pharmaceutica Nv | ImidazoÄ1,2-aÜ(pyrrolo, thieno or furano)Ä3,2-dÜ azepine derivatives, compositions and methods of use. |
HU223464B1 (en) * | 1992-12-04 | 2004-07-28 | Janssen Pharmaceutica N.V. | Antiallergic 1,2,4-triazolobenzazepine derivatives, process for preparing them and pharmaceutical compositions containing them |
US5629308A (en) * | 1992-12-04 | 1997-05-13 | Janssen Pharmaceutica N.V. | Imidazo [1,2-A] (pyrrolo, thieno or furano) [2,3-D] azepine derivatives |
HU223465B1 (en) * | 1992-12-04 | 2004-07-28 | Janssen Pharmaceutica N.V. | Antiallergic triazolo (pyrrolo, thieni or furano) azepine derivatives, process for preparing them and pharmaceutical compositions containing them |
ATE198480T1 (en) * | 1993-07-13 | 2001-01-15 | Janssen Pharmaceutica Nv | ANTIALLERGIC IMIDAZOAZEPINES |
US5700806A (en) * | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
TW382017B (en) * | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
TW527186B (en) | 1996-03-19 | 2003-04-11 | Janssen Pharmaceutica Nv | Fused imidazole derivatives as multidrug resistance modulators |
HU229406B1 (en) * | 1998-12-19 | 2013-12-30 | Janssen Pharmaceutica Nv | Antihistaminic spiro compounds |
EP1401838B1 (en) * | 2001-06-12 | 2014-03-26 | Janssen Pharmaceutica NV | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
EP1554253A4 (en) * | 2002-06-03 | 2006-09-20 | Smithkline Beecham Corp | Imidazolium cxcr3 inhibitors |
JP5292277B2 (en) * | 2006-03-31 | 2013-09-18 | ビスタコン・フアーマシユーチカルズ・エルエルシー | Eye allergy treatment |
WO2014083571A1 (en) | 2012-11-29 | 2014-06-05 | Neuland Laboratories Limited | A process for the preparation of alcaftadine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL130095C (en) * | 1962-08-31 | |||
US3491103A (en) * | 1963-12-19 | 1970-01-20 | Sandoz Ag | Certain 4h-benzo(4,5)cyclohepta-(1,2-b) thiophenes |
FR1447527A (en) * | 1964-08-11 | 1966-07-29 | Sandoz Sa | New benzo-cyclohepta-thiophenes and their preparation |
US3458522A (en) * | 1967-05-17 | 1969-07-29 | Sandoz Ag | 4-piperidine substituted benzocycloheptaoxazoles and benzocycloheptathiazoles |
US3485846A (en) * | 1967-06-30 | 1969-12-23 | Eugene E Galantay | Benzocycloheptaimidazoles |
US3442903A (en) * | 1967-08-30 | 1969-05-06 | Sandoz Ag | Certain aminopropylidenebenzo(5,6)cyclohepta(1,2-d)thiazoles |
CH531000A (en) * | 1970-03-11 | 1972-11-30 | Sandoz Ag | Process for the preparation of new benzocycloheptathiophenes |
US3960894A (en) * | 1972-01-24 | 1976-06-01 | Sandoz Ltd. | 9-Bromo-or chloro-9,10-dihydro-10-dihydro-10-alkoxy-4H-benzo[4,5]cyclo-hepta[1,2-b]thiophen-4-ones |
US3994915A (en) * | 1972-06-30 | 1976-11-30 | Sandoz, Inc. | Preparation of substituted oxazoles |
CH579077A5 (en) * | 1972-08-17 | 1976-08-31 | Sandoz Ag | Antiallergic benzo(4,5) cyclohepta(1,2-b)-thiophene derivs - prepd by reacting 4-(4-piperidinylidene)-4 H-benzo(4,5)6 cyclohepta(1,2-b)thiophen-9(10H)-one with a benz(hydr)yl halide |
US4148903A (en) * | 1977-07-28 | 1979-04-10 | Merck & Co., Inc. | Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines |
US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
US4355036A (en) * | 1980-06-19 | 1982-10-19 | Schering Corporation | Tricyclic-substituted piperidine antihistamines |
EP0047226B1 (en) * | 1980-09-02 | 1985-05-15 | Sandoz Ag | Piperidylidene derivatives, their production and pharmaceutical compositions containing them |
US4596809A (en) * | 1985-03-25 | 1986-06-24 | Schering Corporation | Substituted 1,8-naphthyridinones, useful as anti-allergic agents |
US4826853A (en) * | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
EP0411048A1 (en) * | 1988-04-28 | 1991-02-06 | Schering Corporation | Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use |
WO1989010363A1 (en) * | 1988-04-28 | 1989-11-02 | Schering Corporation | Fused polycyclic compounds, compositions, methods of manufacture and their use as paf antagonists, antihistamines and/or antiinflammatory agents |
CA2004211A1 (en) * | 1988-11-30 | 1990-05-31 | Masataka Syoji | Piperidine derivatives and hyportensives containing the same |
-
1991
- 1991-10-04 DE DE69110685T patent/DE69110685T2/en not_active Expired - Fee Related
- 1991-10-04 AT AT91920026T patent/ATE124045T1/en not_active IP Right Cessation
- 1991-10-04 AU AU89025/91A patent/AU8902591A/en not_active Abandoned
- 1991-10-04 CA CA002093797A patent/CA2093797C/en not_active Expired - Fee Related
- 1991-10-04 JP JP3518357A patent/JPH089616B2/en not_active Expired - Lifetime
- 1991-10-04 EP EP91920026A patent/EP0552292B1/en not_active Expired - Lifetime
- 1991-10-04 US US08/039,038 patent/US5393753A/en not_active Expired - Fee Related
- 1991-10-04 WO PCT/US1991/007156 patent/WO1992006981A1/en active Search and Examination
-
1996
- 1996-10-03 HK HK186696A patent/HK186696A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69110685T2 (en) | 1995-11-09 |
JPH05508661A (en) | 1993-12-02 |
ATE124045T1 (en) | 1995-07-15 |
EP0552292A1 (en) | 1993-07-28 |
JPH089616B2 (en) | 1996-01-31 |
CA2093797A1 (en) | 1992-04-11 |
CA2093797C (en) | 1998-09-22 |
HK186696A (en) | 1996-10-11 |
AU8902591A (en) | 1992-05-20 |
US5393753A (en) | 1995-02-28 |
WO1992006981A1 (en) | 1992-04-30 |
DE69110685D1 (en) | 1995-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0552292B1 (en) | Substituted imidazobenzazepines and imidazopyridoazepines | |
EP0553191B1 (en) | Pyridine and pyridine n-oxide derivatives of diarylmethyl- piperidines or piperazines, compositions and use thereof | |
US5159083A (en) | Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands | |
US6300360B1 (en) | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands | |
US5607933A (en) | 3-arylcarbonyl-1(C-attached-N-heteryl)-1H-indoles | |
US4826853A (en) | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use | |
KR100256707B1 (en) | Novel deazapurine derivatives; a new class of crf1 specific ligands | |
DE4129603A1 (en) | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS | |
US5514687A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and method of use | |
CH678427A5 (en) | ||
US5847136A (en) | Deazapurine derivatives; a new class of CRF1 specific ligands | |
US4782055A (en) | Imidazopyridine compounds useful in the treatment of ulcers | |
US5430032A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use | |
US4524146A (en) | Certain -2-heterocycle substituted pyrazoloquinolines | |
IE61740B1 (en) | 6,11-Dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta [1,2-b]pyridines and compositions and methods of use | |
US4740513A (en) | Methyl substituted imidazol-1-yl quinolones | |
EP0642514B1 (en) | Bridged bis-aryl carbinol derivatives, compositions and methods of use | |
US4503060A (en) | 3-Imino-3H-dibenzo-[c,f]-imidazo-[1,5-a]azepine pharmaceuticals | |
US5283242A (en) | Substituted benzimidazoles and quinazolines as antihypertensives | |
US5804685A (en) | Deazapurine derivatives: a new class of CRF1 specific ligands | |
US3813412A (en) | Certain triazolyl benzhydrol compounds | |
JPS59225181A (en) | 2-heteroaryl-indole, manufacture and medicine | |
EP1776366B1 (en) | Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors | |
US5998416A (en) | Piperazine, piperidine and tetrahydropyridine derivatives as 5-HT receptor agonists | |
US4826854A (en) | Certain cycloalka-(b)-pyrazolo(3,4-d)-pyridin-3-one derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930407 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19940111 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT Effective date: 19950621 Ref country code: BE Effective date: 19950621 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19950621 Ref country code: AT Effective date: 19950621 Ref country code: ES Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19950621 Ref country code: DK Effective date: 19950621 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19950621 |
|
REF | Corresponds to: |
Ref document number: 124045 Country of ref document: AT Date of ref document: 19950715 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 69110685 Country of ref document: DE Date of ref document: 19950727 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19950921 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19951031 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20000918 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20001009 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20001030 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20010103 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011031 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20011004 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020702 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |